Document is current
Any future updates will be listed below
-
Authors
Schenker, Michael
Burotto, Mauricio
Richardet, Martin
Ciuleanu, Tudor-Eliade
Gonçalves, Anthony
Steeghs, Neeltje
Schoffski, Patrick
Ascierto, Paolo A https://orcid.org/0000-0002-8322-475X
Maio, Michele
Lugowska, Iwona
Lupinacci, Lorena
Leary, Alexandra
Delord, Jean-Pierre
Grasselli, Julieta
Tan, David S P
Friedmann, Jennifer
Vuky, Jacqueline
Tschaika, Marina
Konduru, Somasekhar
Vemula, Sai Vikram
Slepetis, Ruta
Kollia, Georgia
Pacius, Misena
Duong, Quyen
Huang, Ning
Doshi, Parul
Baden, Jonathan https://orcid.org/0000-0002-9423-8305
Di Nicola, Massimo https://orcid.org/0000-0002-7689-5774
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03668119 at ClinicalTrials.govnct03668119 at ClinicalTrials.govDocuments that mention this clinical trial
Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy
https://doi.org/10.1136/jitc-2022-005924
Evaluation of tissue- and plasma-derived tumor mutational burden (TMB) and genomic alterations of interest in CheckMate 848, a study of nivolumab combined with ipilimumab and nivolumab alone in patients with advanced or metastatic solid tumors with high TMB
https://doi.org/10.1136/jitc-2023-007339
Trends in clinical development of pediatric cancer for PD-1 and PD-L1 inhibitors: an analysis of ClinicalTrials.gov
https://doi.org/10.1136/jitc-2021-002920
Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden
https://doi.org/10.1136/jitc-2024-008872
nct03668119 at ClinicalTrials.govDocuments that mention this clinical trial
Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy
https://doi.org/10.1136/jitc-2022-005924
Evaluation of tissue- and plasma-derived tumor mutational burden (TMB) and genomic alterations of interest in CheckMate 848, a study of nivolumab combined with ipilimumab and nivolumab alone in patients with advanced or metastatic solid tumors with high TMB
https://doi.org/10.1136/jitc-2023-007339
Trends in clinical development of pediatric cancer for PD-1 and PD-L1 inhibitors: an analysis of ClinicalTrials.gov
https://doi.org/10.1136/jitc-2021-002920
Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden
https://doi.org/10.1136/jitc-2024-008872
Documents that mention this clinical trial
Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy
https://doi.org/10.1136/jitc-2022-005924
Evaluation of tissue- and plasma-derived tumor mutational burden (TMB) and genomic alterations of interest in CheckMate 848, a study of nivolumab combined with ipilimumab and nivolumab alone in patients with advanced or metastatic solid tumors with high TMB
https://doi.org/10.1136/jitc-2023-007339
Trends in clinical development of pediatric cancer for PD-1 and PD-L1 inhibitors: an analysis of ClinicalTrials.gov
https://doi.org/10.1136/jitc-2021-002920
Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden
https://doi.org/10.1136/jitc-2024-008872
-
Funding
Funding for this research was provided by:
Bristol Myers Squibb (N/A)
- License Information
